Zijn er problemen met de
experimentele en niet-gevalideerde 'Phelix Phage Borrelia test'?
De sites van Phelix Research & Development; Bron
https://zb14927861.phelix.org.uk/team/ en Team Phelix Research & Development; Bron
http://phelix.info/en/about/team/https: ... g.uk/team/ en van Phelix France zijn uit de lucht gehaald?
..What is Phelix?
Phelix Research & Development is a medical research charity. The charity works hand in hand with Phelix France, registered in France as an ‘Association d’Intérêt Général’.
Its team is a strong co-partnership of healthcare professionals (practitioners, immunologists and university researchers, amongst them Leicester University) and volunteers, working together to reach the charity’s key objectives.
Phelix was set up with the aim of researching diagnostic techniques, prevention methods and, ultimately, treatment plans for chronic infectious diseases thought to be responsible for some of the main neurodegenerative and neurobehavioural conditions. Overall, we intend to protect and promote the health of the general public.
Currently, the charity is focussed on supporting research surrounding bacteriophage viruses and their potential uses in chronic infection. Could bacteriophages provide an alternative to antibiotics, providing a solution to the problem of increasing antibiotic resistance, one of the largest threats to global health?
Before reaching this stage, research is required in the development of new and more sensitive tests for such chronic infections.
The genus of bacteria identified as a target for research being carried out by the Phelix team initially is called Borrelia spp. Many of the species within this genus are commonly known to be carried by ticks and lice and can cause Lyme disease, if spread to humans.
Simultaneously, work is being done to give further insight into the pathology and physiology of major neurodegenerative conditions, specifically neuroborreliosis, autism spectrum disorder and Alzheimer’s disease. This investigation is to provide a firm basis for Phelix’s future research into the relationship between chronic infection and neurodegeneration.
Phelix uses a variety of means to fulfil its mission objectives.
These include:
- Funding relevant research programmes (e.g the Collaborative Research Agreement with Leicester University).
- Organising fund-raising events to support our research objectives.
- Organising scientific meetings, educational programmes and training courses in the relevant scientific areas.
- Promoting interdisciplinary and international research synergy by financing exchanges between laboratories with corresponding aims.
More generally, Phelix undertakes these and other associated activities to serve public health interests by facilitating the advancement of scientific research in the field of chronic infectious diseases.
Phelix Research & Development is a charity registered in England and Wales with the Charity Number 1156666 (under the Charity Commission regulation and supervision).
Phelix France is an ‘Association d’Interet General’ registered in France under the RNA Number W751223662 (regulated by the French Law)..
Phelix Research & Development is gevestigd in Engeland (Londen). Phelix France is gevestigd in Frankrijk(Parijs).
Phelix Research & Development 29 juli 2017 -
'Borrelia bacteriophages for diagnosis of Lyme Disease (LD) and Relapsing Fever (RF)' by Jinyu Shan1, Ying Jia1, Louis Teulières2, and Martha Clokie1'; Bron
https://www.lymediseaseaction.org.uk/wp ... phages.pdfPhelix Research & Development 1 juni 2019 -
'Bacteriophages as diagnostic markers and therapeutic agents for predicting and treating Borrelia infections and the others' by Jinyu Shan1, Ying Jia1, Louis Teulières2, and Martha Clokie1'; Bron
https://www.lymeresourcecentre.com/syst ... Clokie.pdfPhelix France november 2016 -
'Chronic Lyme and Neurological Disorders: Mechanism & Treatments' by Louis Teulières; Bron
https://aonm.org/wp-content/uploads/201 ... %A8res.pdfPhelix France Phage Test Presentation -
'PHELIX PHAGE TEST: A Breakthrough way to detect intracellular bacteria, and an answer to non-diagnosed ill people'; Bron
https://drive.google.com/file/d/1bDawE- ... r1KgB/viewKan het doek misschien gaan vallen voor de
experimentele en niet-gevalideerde 'Phelix Phage Borrelia test' vergelijkbaar met het '
xmrv/mlv virus-debacle' met de
'xmrv/mlv test' van Red Laboratories?; Bron
viewtopic.php?f=38&t=2435&start=140#p27534Het ontwikkelen van een nieuwe test vraagt veel tijd en geld in verband met de te nemen stappen van
1. proof of principle,
2. proof of concept,
3. onafhankelijke validatie,
4.
implementatie.
De 'Phelix Phage Borrelia test' zit (pas) in fase 2. '
proof of concept'. De ontwikkeling van de andere testen ('Phelix Phage
Bartonella test' en de 'Phelix Phage
Rickettsia test') zitten (pas) in fase 1.'
proof of principle'.
Er zullen verschillende
klinische onderzoeken, dubbelblind gerandomiseerd placebo gecontroleerd onderzoek (Randomized Controlled Trial (RCT)), moeten worden gedaan met verschillende groepen mensen en patiënten om het gestelde te kunnen
bevestigen en bewijzen. Dat proces zal veel tijd(jaren) gaan vragen.
Er zal een goede
onafhankelijke validatie van de test moeten worden gedaan.
Het
EU-proces voor markttoelating is niet doorlopen. Richtlijnen
CE-IVD certificering; Bron
https://www.rvo.nl/onderwerpen/internat ... middelen-0 Dat betekent dat de test voorlopig geen CE-IVD certificering heeft.
..
'R.E.D. Laboratories is offering PHELIX PHAGE TEST: A Breakthrough way to detect intracellular bacteria, and an answer to non-diagnosed ill people'..
Is men (en ook de Nederlandse
promotor van de test; Bron
viewtopic.php?f=5&t=2595&start=10#p28660) veel te voorbarig geweest? En blijkt de genoemde 'breakthrough'(doorbraak) misschien geen 'doorbraak' te zijn? Als dat het geval is zijn er dit keer veel meer mensen (ook kinderen) (wereldwijd) gedupeerd geraakt. Veel mensen-patiënten hebben een verkeerde diagnose
B. miyamotoi/Relapsing Fever en of Borrelia burgdorferi sensu lato (ziekte van Lyme) gesteld gekregen. En een verkeerde behandeling voorgeschreven gekregen.
Lettre d’information PHELIX France - novembre 2020 (Louis Teulières Président) over
Bartonella; Bron
https://iforlyme.org/downloads/phelix-p ... 202011.pdf..Les bénéfices ont entièrement été destinés à financer la recherche de phages spécifiques dans les urines, et d’un test similaire, aussi sensible et spécifique, pour Bartonella (en priorité).
Nous avons réussi à caractériser 3 amorces génétiques de phages spécifiques des Bartonella les plus préoccupantes. Il nous faut les tester maintenant sur des échantillons (proefpersonen) de sang de sujets très suspects cliniquement ou qui ont eu des tests classiques positifs ou douteux et qui continuent à ressentir des symptômes compatibles; n’hésitez pas à nous contacter si c’est le cas.
Nous avions également prévu de tester l’efficacité de plusieurs formulations des enzymes utilisés par les Phages pour percer la paroi afin d’injecter leur ADN et aussi pour détruire les Borrelia. Le confinement de l’Université de Leicester a été effectif dès avril 2020, avec la réquisition par l’état de toutes les machines de tests PCR pour les diagnostics du virus Covid 19, ce qui a considérablement retardé cette partie qui sera mise en place réellement en 2021.
Cependant il y a de bonnes nouvelles! En effet nous avons pu mettre en évidence l’action bactériolytique de ces enzymes sur des cultures de Borrelia (je rappelle que nous sommes une des rares équipes capables de maitriser ces cultures: les Borrelia demandent des conditions et un entretien très spéciaux). Nous allons en 2021 tester des combinaisons enzymatiques qui pourraient être les auxiliaires ou des alternatives aux antibiotiques, les compléments du futur..
Phelix France - Lettre d’information: décembre 2019 (Louis Teulières Président); Bron
https://iforlyme.org/downloads/phelix-p ... 201912.pdf..Depuis fin août le test est mis à la disposition dupublicet près de 2000 tests ont été réalisés. (Provenance surtout Belgique France, RU, Allemagne, Pays bas(Nederland), et depuis notre présentation à l’ILADS de Chicago le 1er novembre, des Etats Unis et du Canada)..
Presentatie van Mijatovic (Red Laboratories)
30 oktober 2020 bij (In)visible International; Bron
https://invisible.international/Presentatie
'Why taking Phelix Phage Test' vanaf 1:41:25 minuten; Bron
https://www.youtube.com/watch?v=OtfO0noahuc ..a unique Phelix Phage Borrelia test is a breakthrough way to detect intracellular bacteria, and an answer to non-diagnosed chronic lyme patients..
..It is a direct test, in contrast to alle existing indirect tests (Elisa, Western Blot, LTT/Elispot tests)..
..The overall high expansion of undiganosed Lyme disease cases worldwide might be linked to the screening choice focusing only on Borrelia burgdorferi sensu lato and only rarely testing for B. relapsing fever and B. miyamotoi while they seem to be much more prevalent, according to our data obtained both on human and tick samples..
..after more than 2 years of testing and more than 6000 samples analysed by the Phelix Phage Borrelia test, this innovative testing approach led to an extremely interesting discovery - far more (mainly late stage) patients were tested positive for strains from Borrelia relaping fever group (B. miyamotoi, B. hermsii, etc) compared to what was initially expected i.e. Borrelia burgdorferi sensu lato species..
..the enlarged study made by Red Laboratories on European ticks (mainly from Belgium, France and Norway) using Phelix Phage Borrelia test shows so far that B. miyamotoi was detected in 32/110 ticks, B. relapsing fever in 46/110, while Borrelia burgdorferi ss in 2/110 and B. afzelii & garinii in 9/110. In addition, the same tick samples were subjected to two additional Borrelia burgdorferi sl testing methods CE IVD qPCR (which detected only 2/110 positive Borrelia burgdorferi samples) and Hybrispot (PCR + dot blot which detected 7/110 positive Borrelia burgdorferi samples). This is a still ongoing study and once completed the results will be submitted for publication..
..In order to further compare and validate this novel Phage-based diagnostics Red Laboratories is looking for partnerships with health-care facilities and practitioners involved in infectious diseases (Lyme and others) and chronic conditions needing to rely on much more sensitive test
- Repositories/Biobanks
- Hospitals and Clinics
- Reference Centers
- Healthcare practitioners..
..Our goal is to get the Phage-based diagnostics officially validated on a large scale that would stimulate official bodies from different countries to acknowledge its value over the two-tier testing and recomment it as a standard-of-care testing method..
..We wish to make available our exclusive unique Phage-based Borrelia detection test to patients worldwide..
..We are working on setting up Phage-based testing for other TBIs, and especially the one for Bartonella. We are looking for Bartonella samples collections/repositories/biobanks in order to challenge and validate Phage-based testing for Bartonella..
..Red Laoratories is ISO 9001: 2015 certified..
Red Laboratories noemt een KIWA certificaat (ISO 9001: 2015 certified). KIWA; Bron
https://www.kiwa.com/nl/nl/ en Bron
http://www.allesduurzaam.nl/keurmerken/ ... ertificaat Een Kiwa-Certificaat is een kwaliteitsverklaring voor (consumenten)producten zoals dubbelglas, douchekoppen en kranen. Het keuringsinstituut geeft daarnaast Kiwa-Certificaten uit aan systemen zoals rioleringen, verwarmingsinstallaties, waterleidingen, en managementsystemen, maar ook aan bedrijven die bijvoorbeeld olietanks saneren.
Het zou interessant zijn als een groep
onafhankelijke geaccrediteerde medische laboratoria (ISO 15189); Bron
https://www.rva.nl/medische-laboratoria/ de 'Phelix Phage Borrelia test' (
PCR) van Red Laboratories kunnen gaan
verifiëren en valideren.
Red Laboratoris heeft
géén ISO 15189 accreditatie van het BELAC België (de Belgische Accreditatie-instelling - Medische laboratoria (MED); Bron
https://economie.fgov.be/nl/themas/kwal ... atoria-med).